What is the role of thrombolytic therapy in the management of patients at intermediate risk of embolism (PE)?

Updated: Jun 06, 2019
  • Author: Daniel R Ouellette, MD, FCCP; Chief Editor: Zab Mosenifar, MD, FACP, FCCP  more...
  • Print
Answer

Until randomized clinical trials demonstrate a clear morbidity or mortality benefit, the role of thrombolytic therapy in the management of acute pulmonary embolism will remain controversial (especially in the management of intermediate-risk patients). [84, 85, 86] The currently accepted indications for thrombolytic therapy include hemodynamic instability (systolic BP < 90 mm Hg) or a clinical risk factor assessment that suggests that hypotension is likely to develop.


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!